EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The incretin effect: An interview with Dr. Daniel Drucker

University of Toronto Medical Journal · 11.05.2026 · 103 (2)

DOI: 10.33137/utmj.v103i2.47411 ↗

Kurz gefasst

Fachartikel in der Zeitschrift University of Toronto Medical Journal, online erschienen am 11.05.2026. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dr. Daniel Drucker is a clinician scientist at the Lunenfeld-Tanenbaum Research Institute, University of Toronto. His laboratory studies the translational biology of glucagon-like peptides (GLPs). His work in this space helped define the biological actions of GLP-1 and laid the scientific foundation for the development of GLP-1-based therapies globally, which are now widely used in the treatment of diabetes and obesity.

Zitieren

APA

(2026). The incretin effect: An interview with Dr. Daniel Drucker. University of Toronto Medical Journal, 103(2). https://doi.org/10.33137/utmj.v103i2.47411

Vancouver

The incretin effect: An interview with Dr. Daniel Drucker. University of Toronto Medical Journal. 2026;103(2). doi:10.33137/utmj.v103i2.47411

BibTeX
@article{euvimed2026,
  title = {The incretin effect: An interview with Dr. Daniel Drucker},
  journal = {University of Toronto Medical Journal},
  year = {2026},
  volume = {103},
  number = {2},
  doi = {10.33137/utmj.v103i2.47411}
}
Kostenlos starten →